Trasylol Risks Outweigh Rewards

Trasylol, the anti-bleeding agent used with patients undergoing cardiac surgery, has been found to increase the risk of death by 50%.  A five-year study of 3876 patients given aprotinin also had a significantly higher death rate than those given two similar drugs to prevent bleeding.
Researchers from the Ischemia Research and Education Foundation in San Bruno, California, assessed survival rates at six weeks, six months and annually for five years among patients undergoing coronary artery bypass graft (CABG) surgery at 62 medical centres around the world.